Skip to content

Orange Book Blog

At the intersection of Patent and FDA Law

    • About
    • Authors
    • Disclaimer

Recent Posts

  • Hikma v. Vanda: Oral Argument Recap
  • Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
  • Should ANDA filers be using the PTAB to mount early challenges to OB patents?
  • Switching to WordPress
  • Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases

  • Twitter
  • Facebook
  • Instagram

Follow-on Biologics Bill Approved by Senate Committee, Moves On to Full Senate

June 27, 2007

MarketWatch.com is reporting this afternoon that the Senate Committee on Health, Education, Labor and Pensions has voted in favor of the Biologics Price Competition and Innovation Act of 2007.  It is unclear whether the Committee amended the bill before voting on it.  The bill will now move to the Senate floor.

RELATED READING:

  • Bloomberg
  • Pharmalot

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook
Like Loading…
Posted in Biosimilars

Leave a comment Cancel reply

←Senate Committee To Vote Wednesday on Bipartisan Follow-on Biologics Bill
Federal Circuit Affirms Validity of Takeda’s ACTOS Patent, Rejecting Alphapharm’s Obviousness Arguments→

Blog at WordPress.com.

  • Comment
  • Reblog
  • Subscribe Subscribed
    • Orange Book Blog
    • Already have a WordPress.com account? Log in now.
    • Orange Book Blog
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • View post in Reader
    • Manage subscriptions
    • Collapse this bar
%d